早期生长菌落用于自动化与手工肉汤微量稀释药敏试验的性能评估
本研究评估了将菌落孵育6小时(早期生长)后直接用于手工肉汤微量稀释(Sensititre)和自动化药敏系统(BD Phoenix)的可行性,并与标准18-24小时孵育的药敏结果比较。在革兰阳性及阴性临床分离株中,早期生长药敏与标准方法总体一致性高,提示可缩短药敏周转时间而不增加额外成本。
要点
- 早期生长药敏(6小时孵育)与标准18-24小时药敏结果一致性高。
- 肠杆菌目在Phoenix系统上早期生长药敏的MiE为1.3%、ME为0.17%、VME为1.1%。
- 葡萄球菌和肠球菌在Phoenix系统上早期生长药敏无MiE、ME或VME。
核心结论
- 早期生长药敏(孵育6小时)是缩短CLSI推荐孵育时间的可行策略,且与参考方法保持高度一致性。
研究设计与样本
- 先对革兰阴性(n=5)和革兰阳性(n=2)质控菌株进行6或24小时孵育的概念验证研究。
- 随后纳入革兰阳性(Phoenix n=49;Sensititre n=46)和革兰阴性(Phoenix n=81;Sensititre n=61)临床分离株,比较早期生长药敏与标准生长药敏。
主要发现
- 概念验证研究中,6或24小时孵育的Sensititre和Phoenix药敏结果均显示100%基本一致性。
- Sensititre共测试1666个菌-药组合(革兰阳性560、革兰阴性1106),Phoenix共测试1927个(革兰阳性409、革兰阴性1518)。
- 肠杆菌目Phoenix早期生长药敏:MiE 1.3%、ME 0.17%、VME 1.1%;铜绿假单胞菌MiE 0.18%,无ME或VME。
- 肠杆菌目Sensititre早期生长药敏:MiE 1.5%,无ME或VME;铜绿假单胞菌MiE 2.8%、ME 6.6%,无VME。
- 葡萄球菌和肠球菌Phoenix早期生长药敏无MiE、ME或VME;Sensititre对葡萄球菌MiE 3.14%、ME 0.3%、VME 2.99%,对肠球菌MiE 6.8%、ME 0.09%,无VME。
临床怎么用
- 可考虑对早期生长菌落(孵育6小时)直接进行肉汤微量稀释或自动化药敏试验以缩短报告时间。
- 不同菌种和药敏系统组合的误差率存在差异,需结合本实验室系统验证后应用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Prolonged turnaround times (TAT) represent a major limitation to current automated susceptibility testing systems and manual susceptibility-testing methods such as broth microdilution. As a result, targeted therapy for patients may be delayed, portending suboptimal clinical outcomes. One contributing factor is the 18-24 h of incubation prior to antimicrobial-susceptibility testing (AST) recommended by the Clinical Laboratory Standards Institute (CLSI) and some automated AST manufacturers. This study evaluates the performance of AST by manual broth microdilution (Thermo Fisher Sensititre) and an automated AST system (BD Phoenix) on isolates incubated for 6 h (early growth AST, egAST) compared with 18-24 h (standard growth AST, sgAST). An initial proof-of-concept study conducted on gram-negative (n = 5) and gram-positive (n = 2) quality control strains incubated for 6 or 24 h prior to Sensititre and Phoenix demonstrated 100% essential agreement. Subsequently, we evaluated the performance of egAST on gram-positive (n = 49, Phoenix; n = 46 Sensititre) and gram-negative (n = 81 Phoenix; n = 61 Sensititre) patient-derived isolates with diverse resistance profiles compared with sgAST. In total, 1,666 organism-drug combinations were tested by Sensititre (560 gram-positive and 1,106 gram-negative) and 1,927 by Phoenix (409 gram-positive and 1,518 gram-negative). For Enterobacterales, egAST using Phoenix revealed 1.3% minor errors (MiE), 0.17% major errors (ME), and 1.1% very major errors (VME) compared with sgAST. Phoenix egAST performance for Pseudomonas aeruginosa revealed 0.18% MiE and no ME or VME. Similarly, egAST of Enterobacterales by Sensititre revealed 1.5% MiE and no ME or VME, whereas 2.8% MiE, 6.6% ME, and no VME were observed for P. aeruginosa. For Staphylococcus spp. and Enterococcus spp., there were no MiE, ME, or VME on the Phoenix system, whereas early growth Sensititre showed 3.14% MiE, 0.3% ME, and 2.99% VME for Staphylococcus spp. and 6.8% MiE, 0.09% ME, and no VME for Enterococcus spp. Taken together, these data suggest that egAST represents a viable strategy to reduce the prolonged incubation period currently recommended by CLSI and select automated AST manufacturer guidelines without incurring any additional costs while simultaneously maintaining high concordance with reference standard methods.IMPORTANCETraditional antimicrobial-susceptibility testing (AST) methods typically span several days from the time of organism isolation. The majority of this time is spent waiting for a cultured isolate to incubate up to 1 day prior to AST. There exists an unmet need to provide more rapid AST as various rapid methods have been shown to reduce exposure to broad-spectrum antibiotics that select for antimicrobial resistance, shorten hospital stays, and improve clinical outcomes. Simultaneously, there is a need to ensure that rapid AST approaches are readily implemented in the clinical microbiology laboratory, with little to no added financial burden. This study demonstrates a cost-considerate and practical approach to reduce AST turnaround times by up to 18 h through the use of early growth isolates in combination with two commercial AST systems. The findings from this study complement those of previous reports describing the largely acceptable performance of disk diffusion using early growth isolates.
引用
- Osborn LJ, Osborn L, Ibarra-Flores I, et al. Performance evaluation of early growth isolates for automated and manual broth microdilution antimicrobial-susceptibility testing. J Clin Microbiol. 2025. PMID: 40586583. doi:10.1128/jcm.00236-25
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。